What is the recommended inpatient care plan for a patient admitted with Moyamoya disease?

Hospital Care Plan for Moyamoya Disease

Admitted patients with Moyamoya disease require meticulous hemodynamic management prioritizing cerebral perfusion over standard stroke protocols, with blood pressure targets individualized to presentation type (ischemic vs hemorrhagic) and immediate neurosurgical consultation for revascularization planning.

Initial Assessment and Risk Stratification

Upon admission, determine the presentation phenotype immediately:

• Ischemic presentation: Transient ischemic attacks, completed stroke, or symptoms of hypoperfusion (typically in watershed territories)
• Hemorrhagic presentation: Intraparenchymal or intraventricular hemorrhage from rupture of fragile moyamoya collaterals

Document the Suzuki angiographic stage if known, as advanced stages (IV-VI) indicate more severe disease with higher risk of complications 1. Assess for posterior circulation involvement, which correlates with worse clinical outcomes and higher hemorrhage recurrence 1.

Hemodynamic Management: The Critical Divergence

For Ischemic Presentation

Maintain permissive hypertension with systolic blood pressure targets of 120-160 mmHg to preserve collateral-dependent cerebral perfusion 2. This directly contradicts standard acute stroke management because these patients depend entirely on fragile collateral vessels for brain perfusion.

• Aggressive preoperative hydration to sustain cerebral perfusion 3
• Target normovolemia to mild hypervolemia 3
• Avoid hypotension at all costs—cerebral perfusion depends on collaterals

For Hemorrhagic Presentation

Use individualized blood pressure targets balancing hematoma expansion risk against collateral perfusion needs, typically systolic 120-160 mmHg rather than aggressive reduction to <140 mmHg 2. Standard post-ICH protocols that aggressively lower blood pressure can precipitate catastrophic ischemia in the contralateral hemisphere or watershed zones.

Respiratory and Metabolic Management

• Maintain strict normocapnia: Both hypercapnia and hypocapnia are dangerous
  • Hypocapnia causes vasoconstriction and cerebral ischemia
  • Hypercapnia may precipitate steal phenomenon
• Maintain normothermia: Hypothermia induces cerebral vasospasm 3
• Optimize oxygen delivery: Target SpO2 >95% 3
• Manage hematocrit appropriately: In ischemic presentations, maintain adequate oxygen-carrying capacity to prevent further ischemia 3

Medical Therapy

Initiate antiplatelet therapy (aspirin 81-325 mg daily) for non-hemorrhagic presentations 1, 4. Despite historical concerns about hemorrhage risk, recent evidence shows no consistent signal of increased bleeding with antiplatelet use in ischemic moyamoya 1. The European Stroke Organisation guidelines recommend long-term antiplatelet therapy as it may reduce embolic stroke risk 4.

Critical caveat: Antiplatelet therapy should be avoided or held in hemorrhagic presentations until neurosurgical evaluation is complete.

Vascular Risk Factor Management

Aggressively manage coexisting conditions:

• Diabetes: Independent predictor of recurrent ischemic stroke even after surgical treatment 1
• Hypertension: Risk factor for events in asymptomatic patients 1
• Dyslipidemia: Consider statin therapy, which may improve postoperative collateral circulation 1

Medications to Avoid

Do not use vasoconstrictive or vasodilatory agents:

• Avoid triptans, ergots, and calcitonin gene-related peptide antagonists (cause vasoconstriction) 1
• Avoid calcium channel blockers and beta-blockers for blood pressure control (may impair perfusion) 1
• These restrictions apply particularly to headache management

Neurological Monitoring

Perform frequent neurological assessments (every 1-2 hours initially) 5:

• Monitor for new focal deficits indicating ischemia or hemorrhage expansion
• Assess for seizure activity (maintain low threshold for continuous EEG)
• Watch for signs of increased intracranial pressure

Immediate Neurosurgical Consultation

All admitted moyamoya patients require urgent neurosurgical evaluation for revascularization planning 4. Surgical revascularization is the definitive treatment and dramatically reduces stroke recurrence.

Surgical Timing Considerations

• For ischemic presentations: Plan surgery 6-12 weeks after the last cerebrovascular event 4
• For hemorrhagic presentations: Based on low-quality evidence from one RCT, direct bypass surgery is recommended 4
• Surgery should be performed in centers with specialized moyamoya expertise

Diagnostic Workup During Admission

If diagnosis not yet confirmed:

• Cerebral angiography (DSA) remains gold standard 6
• MRA acceptable if all typical findings present 6
• Hemodynamic assessment with perfusion imaging (CT perfusion, MR perfusion, or PET) to guide surgical planning 4
• Posterior circulation assessment to identify involvement associated with worse outcomes 1

Contraindications and Pitfalls

Do not perform mechanical thrombectomy if bilateral M1 occlusions with distal reconstitution are seen on CTA—this pattern suggests moyamoya rather than acute thromboembolism 2.

Do not apply standard post-stroke or post-ICH blood pressure protocols without considering the unique hemodynamic requirements of moyamoya 2.

Avoid dehydration: NPO status, diuretics, and inadequate IV fluids can precipitate ischemic events 3.

Postoperative Care (If Surgery Performed During Admission)

Critical care nursing is among the most complex in neuroscience 5:

• Monitor for hyperperfusion syndrome: Headache, seizures, focal deficits, or hemorrhage
• Adjust blood pressure targets postoperatively: Maintain normocapnia and avoid hypertension to prevent cerebral hyperperfusion 3
• Extubation decisions: Consider baseline neurological function 3

Discharge Planning

• Arrange outpatient neurosurgical follow-up within 2-4 weeks
• Continue antiplatelet therapy (if non-hemorrhagic)
• Strict vascular risk factor control
• Patient education on avoiding dehydration, hyperventilation, and Valsalva maneuvers
• Plan for long-term neuroimaging surveillance to assess disease progression 4